245 related articles for article (PubMed ID: 15041394)
1. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
[TBL] [Abstract][Full Text] [Related]
2. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
3. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
4. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
Lin M; Ming A; Zhao M
Clin Transplant; 2006; 20(3):325-9. PubMed ID: 16824149
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2R antagonists in the prevention of acute rejection in living donor transplantation.
Ivanovski N; Popov Z; Kolevski P; Cakalaroski K; Spasovski G; Sikole A; Paneva-Masin J
Transplant Proc; 2001; 33(7-8):3203-4. PubMed ID: 11750374
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
7. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
[TBL] [Abstract][Full Text] [Related]
8. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection.
Pham K; Kraft K; Thielke J; Oberholzer J; Sankary H; Testa G; Benedetti E
Transplant Proc; 2005 Mar; 37(2):899-902. PubMed ID: 15848569
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function.
González E; Gutiérrez E; Hernández Y; Roselló G; Gutiérrez MJ; Martínez EG; Manzanera MJ; García JA; Praga M; Morales JM; Andrés A
Transplant Proc; 2005 Nov; 37(9):3736-7. PubMed ID: 16386522
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin 2-receptor antibodies: a comparative study with polyclonal antibodies in kidney transplantation: preliminary results.
Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimarães S
Transplant Proc; 2000 Dec; 32(8):2623-5. PubMed ID: 11134730
[No Abstract] [Full Text] [Related]
11. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
Vincenti F; Kirkman R; Light S; Bumgardner G; Pescovitz M; Halloran P; Neylan J; Wilkinson A; Ekberg H; Gaston R; Backman L; Burdick J
N Engl J Med; 1998 Jan; 338(3):161-5. PubMed ID: 9428817
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies.
Kircher B; Lätzer K; Gastl G; Nachbaur D
Clin Exp Immunol; 2003 Dec; 134(3):426-30. PubMed ID: 14632747
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
Madsen M; Svendsen UG
Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
[TBL] [Abstract][Full Text] [Related]
16. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation.
Campara M; Tzvetanov IG; Oberholzer J
Expert Opin Biol Ther; 2010 Jun; 10(6):959-69. PubMed ID: 20415630
[TBL] [Abstract][Full Text] [Related]
18. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
Savo AM; Book BK; Henson S; Hakimi J; Pescovitz MD
Transplant Proc; 1999; 31(1-2):1182-3. PubMed ID: 10083528
[No Abstract] [Full Text] [Related]
19. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2001 Sep; 16(9):1756-60. PubMed ID: 11522853
[No Abstract] [Full Text] [Related]
20. The role of newer monoclonal antibodies in renal transplantation.
Vincenti F
Transplant Proc; 2001; 33(1-2):1000-1. PubMed ID: 11267163
[No Abstract] [Full Text] [Related]
[Next] [New Search]
